PPIDT00045
Drug Information
| Name | Adalimumab |
|---|---|
| Sequence | DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
| DrugBank_ID | DB00051 |
| Type | biotech |
| Indication | Adalimumab is indicated for the following conditions:[L49101] - Moderately to severely active Rheumatoid Arthritis (RA) in adults, as monotherapy or in combination with [methotrexate] or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).[L42290, L42495, L42935, L44953, L45643, L45818, L49101] - Moderately to severely active polyarticular Juvenile Idiopathic Arthritis (JIA) in patients two years of age and older, as monotherapy or in combination with [methotrexate].[L42290, L42495, L42935, L44953, L45643, L45818, L49101] - Psoriatic Arthritis (PsA) in adults.[L42290, L42495, L42935, L44953, L45643, L45818, L49101] - Ankylosing Spondylitis (AS) in adults.[L42290, L42495, L42935, L44953, L45643, L45818, L49101] - Moderately to severely active Crohn’s Disease (CD) in adults and pediatric patients six years of age and older.[L42290, L42495, L42935, L44953, L45643, L45818, L49101] - Moderately to severely active Ulcerative Colitis (UC) in adults. Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.[L42290, L42495, L42935, L44953, L45643, L45818, L49101] - Moderate to severe chronic plaque psoriasis in adult candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate.[L42290, L42495, L42935, L44953, L45643, L45818, L49101] - Moderate to severe Hidradenitis Suppurativa (HS) in adults.[L44953] - Non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients two years of age and older.[L35370] Adalimumab has also been used off-label to treat Pyoderma gangrenosum.[A40001,A40002] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Kit; solution | Subcutaneous |
40 mg / 0.8 mL
|
| Solution | Subcutaneous |
10 mg / 0.2 mL
|
| Kit | Subcutaneous |
|
| Injection, solution | — |
20 mg/0.4ml
|
| Injection, solution | Parenteral; Subcutaneous |
20 MG
|
| Injection, solution | Parenteral; Subcutaneous |
40 MG
|
| Solution | Subcutaneous |
40.00 mg
|
| Solution | Subcutaneous |
50 mg / mL
|
| Injection, solution | Parenteral |
40 MG
|
| Injection, solution | — |
|
| Injection, solution | Subcutaneous |
|
| Injection, solution | Parenteral |
40 MG/0.8ML
|
| Injection, solution | Subcutaneous |
20 mg/0.4ml
|
| Solution | Subcutaneous |
5000000 mg
|
| Injection | Subcutaneous |
10 mg/0.2mL
|
| Injection | Subcutaneous |
20 mg/0.4mL
|
| Injection | Subcutaneous |
20 mg/0.2mL
|
| Injection | Subcutaneous |
80 mg/0.8mL
|
| — | — |
40 mg
|
| Solution | Subcutaneous |
40 mg/0.8ml
|
| Solution | Subcutaneous |
40 mg/0.4mL
|
| Injection, solution | Subcutaneous |
20 MG
|
| Injection, solution | Subcutaneous |
40 MG
|
| Injection, solution | Subcutaneous |
80 mg
|
| Injection, solution | Subcutaneous |
50 mg/ml
|
| Solution | Subcutaneous |
20 mg / 0.4 mL
|
| Injection | Subcutaneous |
|
| Injection, solution | Parenteral; Subcutaneous |
80 MG
|
| Injection, solution; kit | Subcutaneous; Topical |
|
| Injection, solution; kit; swab | Subcutaneous; Topical |
|
| Injection, suspension; kit | Subcutaneous; Topical |
|
| Solution | Subcutaneous |
10 mg / 0.1 mL
|
| Solution | Subcutaneous |
20 mg / 0.2 mL
|
| Solution | Subcutaneous |
40 mg / 0.8 mL
|
| Solution | Subcutaneous |
40 mg / 0.4 mL
|
| Solution | Subcutaneous |
80 mg / 0.8 mL
|
| Solution | Subcutaneous |
80.000 mg
|
| Injection, solution | — |
20 mg/0.2ml
|
| Injection, solution | Parenteral |
40 MG/0.4ML
|
| Injection, solution | — |
40 mg/0.4ml
|
| Injection, solution | Parenteral |
80 MG/0.8ML
|
| Injection, solution | Subcutaneous |
20.0 mg/0.2mL
|
| Injection, solution | Subcutaneous |
40.0 mg
|
| Injection, solution | Subcutaneous |
40 mg/0.4ml
|
| Injection | Subcutaneous |
40 mg
|
| Injection | Subcutaneous |
40 mg/0.8ml
|
| Injection | Subcutaneous |
40.0 mg
|
| Injection, solution | Subcutaneous |
80.0 mg/0.8mL
|
| Solution | Subcutaneous |
4000000 mg
|
| Solution | Subcutaneous |
100 mg
|
| Injection, solution | Subcutaneous |
10 mg/0.1mL
|
| Injection, solution | Subcutaneous |
20 mg/0.2mL
|
| Injection, solution | Subcutaneous |
80 mg/0.8mL
|
| Injection, solution; kit | Subcutaneous |
|
| Injection; kit; swab | Subcutaneous; Topical |
|
| Injection, solution | Parenteral; Subcutaneous |
40 MG/0.8ML
|
| Injection, solution | Subcutaneous |
40 mg/0.8mL
|
| Injection, solution | Intravenous |
40 mg/0.8mL
|
| Injection | Subcutaneous |
20 mg
|
| Injection | Subcutaneous |
40 mg/0.4mL
|
| Injection; kit | Subcutaneous |
|
| Solution | Subcutaneous |
10000000 mg
|
| Solution | Subcutaneous |
10 mg/0.1ml
|
| Injection, solution | — |
40 mg/0.8ml
|